23 septembre 2025|
AI
|2 months agoRoche Reports Breakthrough in Breast Cancer Treatment
Swiss pharmaceutical giant announces positive results from phase III trials combining giredestrant and everolimus treatments, showing significant improvement in patient survival rates.
AI
Generated IllustrationKey Takeaways
AI
- Roche has achieved positive results in the Phase III evERA study for a new breast cancer treatment combination.
- The treatment targets locally advanced or metastatic estrogen receptor-positive (ER+) and human epidermal growth factor receptor-negative (HER2-) breast cancer.
- The new combination therapy is administered orally.
- Roche is currently running five separate clinical programs involving giredestrant.
- Adverse side effects were comparable to the substances administered separately, showing no new safety signals.
By The Numbers
Phase III
Clinical Trial Stage
5
Clinical Programmes
They Said
"Significant increase in the survival time of patients without disease progression."
"The substance is designed to prevent oestrogens from binding to their receptors, thereby interrupting or slowing the progression of cancer cells."